5001262026-04-012026-06-305001262026-04-012026-06-30in-capmkt:OtherExpenses1Member5001262026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500126PGHLNOTLISTEDINE199A01012PROCTER & GAMBLE HEALTH LIMITEDMain BoardEquity2026-04-012027-03-312026-08-062026-06-26INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-08-0613:26:002026-08-0613:43:00Not applicablefalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone3637100000388000003675900000803100000245600000-86500000603900000140000060200000107500000027027000009732000003180000001291200000310300000194000003297000000961500000000096150000031000009646000001660000001057.9257.920057.9257.921. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 6, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company.These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and expressed "Unmodified" conclusion. <br /> <br /> 2. 'This Statement has been prepared in accordance with the Companies ("Indian Accounting Standards") Rules, 2015 ("IND AS") prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. <br /> <br /> 3.The Company does not have a subsidiary, an associate or a joint venture as at 30 June, 2026. <br /> <br /> 4. 'The figures for the preceeding three months ended March 31, 2026, are the balancing figures between the audited figures in respect of the year ended March 31, 2026 and the published unaudited year to date figures upto the third quarter ended December 31, 2025. <br /> <br /> 5. 'The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided. <br /> <br /> 6. 'The unaudited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). <br /> <br /> 7. 'During the quarter ended June 30, 2026, the Company sold its office premises property located at Worli for Rs. 3 334 Lakhs. The carrying amount of the property as at date of sale was Rs. 154 Lakhs. The gain arising from the sale amounting to Rs. 3 180 Lakhs has been disclosed as an exceptional item for the quarter ended June 30, 2026. <br /> <br /> 8. Previous year's / quarter's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's /quarter's classification. <br /> <br /> Note: EPS before Exceptional Item is 38.77Other Expenses1075000000 Re-measurement gains / (losses) on defined benefit plans4100000410000010000003100000